Compare GF & MDXH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | GF | MDXH |
|---|---|---|
| Founded | 1990 | 2003 |
| Country | Germany | Belgium |
| Employees | N/A | N/A |
| Industry | Investment Managers | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 184.9M | 167.8M |
| IPO Year | N/A | 2021 |
| Metric | GF | MDXH |
|---|---|---|
| Price | $11.43 | $3.47 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $7.67 |
| AVG Volume (30 Days) | 28.1K | ★ 123.4K |
| Earning Date | 01-01-0001 | 11-12-2025 |
| Dividend Yield | ★ 0.82% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $103,069,000.00 |
| Revenue This Year | N/A | $23.34 |
| Revenue Next Year | N/A | $22.98 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 21.68 |
| 52 Week Low | $7.38 | $1.35 |
| 52 Week High | $9.41 | $5.33 |
| Indicator | GF | MDXH |
|---|---|---|
| Relative Strength Index (RSI) | 62.87 | 47.75 |
| Support Level | $11.18 | $3.11 |
| Resistance Level | $11.51 | $3.58 |
| Average True Range (ATR) | 0.15 | 0.17 |
| MACD | 0.04 | 0.04 |
| Stochastic Oscillator | 82.96 | 63.25 |
NEW GERMANY FUND INC is a non-diversified, closed-end management investment company. As the investment objective, the fund seeks long-term capital appreciation through investment in middle-market German equities. The fund's portfolio of investment includes investments in different sectors such as the industrials, information technology, material, consumer discretionary, Communication Services, Financials, Consumer Staples, Real Estate, Utilities, Healthcare, Energy, and others. Its portfolio is geographically diversified across the Netherlands, Germany, and Luxembourg.
MDxHealth SA is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. Its tests are based on proprietary genomic, epigenetic, and other molecular technologies and assist physicians with the diagnosis of urologic cancers, the prognosis of recurrence risk, and the prediction of response to a specific therapy. It derives revenues from clinical laboratory service testing or the out-licensing of the company's patented DNA methylation platform and biomarkers. Geographically, it derives revenue from the United States of America (USA) and Europe.